Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment

BMC Vet Res. 2017 Jan 23;13(1):31. doi: 10.1186/s12917-017-0956-0.


Background: The objective of this study was to evaluate and compare the evolution of the profile currently recommended by the International Renal Interest Society (IRIS) (sCr, UPC and sSDMA) with a panel of other different kidney biomarkers during treatment for canine leishmaniosis. This panel included three urinary glomerular biomarkers (uIgG, uCRP and uferritin) and three urinary tubular biomarkers (uGGT, uNAG and uRBP). These biomarkers were measured in two groups of dogs with canine leishmaniosis at IRIS stage I. Group 1: dogs showing proteinuria (UPC > 0.5) before treatment which did not decrease after treatment; Group 2: dogs showing proteinuria before treatment which decreased after treatment.

Results: Group 1 showed no significant changes in any biomarker after treatment. In group 2, among the biomarkers recommended by the IRIS, only UPC showed a significant decrease after treatment. However all biomarkers of glomerular damage showed a significant decrease after treatment, with uIgG/Cr and uCRP/Cr showing the greater decreases. In addition uRBP/Cr and uNAG/Cr showed significant decreases after treatment.

Conclusions: In dogs with leishmaniosis at IRIS stage I that reduced UPC after treatment, there were no significant changes in serum creatinine and sSDMA. However, all the urine biomarkers evaluated with exception of uGGT showed a significant decrease. These decreases were more evident in those markers related with glomerular function, being uIgG/Cr the biomarker more associated with UPC. Further studies involving a larger number of animals and histological analysis of the kidney would be recommended to confirm these findings and evaluate the routine practical use of these urine biomarkers in canine leishmaniosis.

Keywords: Creatinine; Gamma glutamyl-transpeptidase (GGT); Immunoglobulin G (IgG); Kidney; Retinol-binding protein (RBP); Symmetric dimethylarginine (SDMA); UPC; Urine.

MeSH terms

  • Allopurinol / administration & dosage
  • Allopurinol / therapeutic use*
  • Animals
  • Antimetabolites / administration & dosage
  • Antimetabolites / therapeutic use
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / therapeutic use*
  • Biomarkers / urine
  • Dog Diseases / drug therapy*
  • Dog Diseases / urine
  • Dogs
  • Drug Therapy, Combination
  • Kidney Diseases / etiology
  • Kidney Diseases / urine
  • Kidney Diseases / veterinary*
  • Leishmaniasis / drug therapy
  • Leishmaniasis / urine
  • Leishmaniasis / veterinary*
  • Meglumine / administration & dosage
  • Meglumine / therapeutic use*
  • Meglumine Antimoniate
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / therapeutic use*
  • Proteinuria / veterinary


  • Antimetabolites
  • Antiprotozoal Agents
  • Biomarkers
  • Organometallic Compounds
  • Allopurinol
  • Meglumine
  • Meglumine Antimoniate